-
-
-
-
-
-
-
Sanofi climbs as strong Dupixent sales drive Q1 revenue and profit beat
-
-
-
-
-
-
-
DNDi and Sanofi drug receives CHMP positive opinion for sleeping sickness
-
-
-
-
-
-
-
Sanofi (SNY) Tops Q3 EPS by 72c
-
-
-
-
-
-
-
Revvity Announces Program to Revolutionize the Early Detection of Type 1 Diabetes
-
-
-
-
-
-
-
GSK cut to Hold by Berenberg as investors await proof from upcoming drug launches
-
-
-
-
-
-
-
Sanofi to invest at least $20 billion in the US through 2030, growing investments in science and expanding domestic manufacturing
-
-
-
-
-
-
-
Goldman Sachs Starts Sanofi (SAN:FP) (SNY) at Neutral
-
1,203,689 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

